Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 11/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | PYGB | P11216 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14426665 | 1.00 | OGA (0.66) | OGALMNAGBA1ALDH1A1THRB | |
| SCHEMBL31540109 | 0.83 | LMNA (0.53) | OGALMNAGBA1PYGBGAA | |
| SCHEMBL8197445 | 0.82 | OGA (0.64) | OGALMNAGBA1ALDH1A1THRB | |
| SCHEMBL8203562 | 0.82 | OGA (0.64) | OGALMNAGBA1ALDH1A1THRB | |
| SCHEMBL14426666 | 0.80 | OGA (1.00) | OGALMNAGBA1ALDH1A1THRB | |
| SCHEMBL14439290 | 0.80 | OGA (1.00) | OGALMNAGBA1ALDH1A1THRB | |
| SCHEMBL8198477 | 0.78 | OGA (0.63) | OGALMNAGBA1ALDH1A1THRB | |
| SCHEMBL14342859 | 0.78 | OGA (0.59) | OGALMNAGBA1ALDH1A1THRB | |
| SCHEMBL8197969 | 0.78 | OGA (0.63) | OGALMNAGBA1ALDH1A1THRB | |
| SCHEMBL8749204 | 0.73 | OGA (0.43) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802670-B1 | LYSOSOMAL ENZYME ASSAY METHODS AND COMPOSITIONS | UNIV WASHINGTON (US) | 2019-12-25 | — | — | EP | claimed |
| US-20170159103-A1 | METHODS AND COMPOSITIONS FOR ASSAYING THE ACTIVITY OF ONE OR MORE LYSOSOMAL ENZYMES | UNIVERSITY OF WASHINGTON (US) | 2017-06-08 | — | — | US | claimed |
| US-9512463-B2 | Methods and compositions for assaying the activity of one or more lysosomal enzymes | UNIVERSITY OF WASHINGTON (US) | 2016-12-06 | — | — | US | claimed |
| EP-2802670-A1 | LYSOSOMAL ENZYME ASSAY METHODS AND COMPOSITIONS | University of Washington (US) | 2014-11-19 | — | — | EP | claimed |
| US-20140249054-A1 | LYSOSOMAL ENZYME ASSAY METHODS AND COMPOSITIONS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2014-09-04 | — | — | US | claimed |
| WO-2013070953-A1 | LYSOSOMAL ENZYME ASSAY METHODS AND COMPOSITIONS | UNIVERSITY OF WASHINGTON (US) | 2013-05-16 | — | — | WO | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-2802670-B1 | LYSOSOMAL ENZYME ASSAY METHODS AND COMPOSITIONS | UNIV WASHINGTON (US) | 2019-12-25 | — | — | EP | disclosed |
| WO-2003002127-A1 | USE OF AT LEAST ONE GLYCOINHIBITOR SUBSTANCE | GLYKOS FINLAND OY (FI) | 2003-01-09 | — | — | WO | disclosed |
| US-20020081656-A1 | UDP-N-acetylglucosamine: Galactose-beta1,3-N-acetylgalactosamine-alpha-R / N-acetylglucosamine-beta1,3,-N-acetylgalactosamine-alpha-R (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2/4GnT | GLYCOZYM USA INC. | 2002-06-27 | — | — | US | disclosed |
| US-20020028954-A1 | 2-acylamino-2-deoxy-glucono-1,5-lactones, a method for the production thereof, compositions containing them, and uses thereof | UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) (FR) | 2002-03-07 | — | — | US | disclosed |
| EP-1135472-A2 | UDP-N- ACETYL GLUCOSAMINE: GALACTOSE-BETA1, 3-N- ACETYL GALACTOSAMINE-ALPHA-R/ N- ACETYL GLUCOSAMINE -BETA1, 3-N- ACETYL GALACTOSAMINE- ALPHA-R (GlcNAc TO GalNAc) BETA1, 6-N- ACETYL GLUCOSAMINYL TRANSFERASE, C2/4GnT | Clausen, Henrik (DK) | 2001-09-26 | — | — | EP | disclosed |
| EP-1131311-A1 | 2-ACYLAMINO-2-DEOXY-GLUCONO-1,5-LACTONES, METHOD FOR OBTAINING SAME, COMPOSITIONS COMPRISING THEM AND USES | UNIVERSITE PIERRE ET MARIE CURIE PARIS VI (FR) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000034449-A2 | UDP-N- ACETYL GLUCOSAMINE: GALACTOSE-β1, 3-N- ACETYL GALACTOSAMINE- α-R/ N- ACETYL GLUCOSAMINE -β1, 3-N- ACETYL GALACTOSAMINE- α-R (GlcNAc TO GalNAc) β1,6-N- ACETYL GLUCOSAMINYL TRANSFERASE, C2/4GnT | CLAUSEN HENRIK (DK) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000031059-A1 | 2-ACYLAMINO-2-DEOXY-GLUCONO-1,5-LACTONES, METHOD FOR OBTAINING SAME, COMPOSITIONS COMPRISING THEM AND USES | UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) (FR) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028954-A1 | 2-acylamino-2-deoxy-glucono-1,5-lactones, a method for the production thereof, compositions containing them, and uses thereof | ENGASE, FUT5, CHIT1 | OGA 31/4885LMNA 1710/4885GBA1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.